VolitionRx’s (VNRX) Buy Rating Reiterated at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock.

VNRX has been the subject of several other reports. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com initiated coverage on VolitionRx in a research note on Tuesday. They issued a “sell” rating on the stock.

VolitionRx Stock Down 2.8 %

Shares of NYSE VNRX traded down $0.02 during trading hours on Tuesday, hitting $0.60. 61,874 shares of the stock were exchanged, compared to its average volume of 107,056. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.10. The firm has a fifty day moving average price of $0.61 and a 200-day moving average price of $0.65. The company has a market cap of $55.69 million, a PE ratio of -1.67 and a beta of 1.20.

Insider Activity at VolitionRx

In other VolitionRx news, CEO Cameron John Reynolds bought 139,811 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by company insiders.

Institutional Trading of VolitionRx

A number of institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the fourth quarter valued at approximately $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx in the fourth quarter valued at approximately $36,000. Northern Trust Corp raised its position in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. boosted its holdings in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.